lifenews.com
2026-09-11
Last week, Senator Bill Cassidy (R-La.), chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, released a new report: "Mifepristone Without Guardrails: An Investigation Into How Chemical Abortion Drug Makers Are Putting Mothers and Babies At Risk." The report follows months of investigation by the committee into the business practices of the three companies that manufacture mifepristone, the first drug taken in the chemical abortion regimen, often referred to as "the abortion pill."
The report confirms what many in the pro-life movement had already suspected -- mifepristone manufacturers are contributing to the current abortion drug crisis happening in our country by failing to follow their obligations under FDA regulations. This shouldn't come as a big surprise, but several findings in the report are notable.
For background, the three manufacturers (or "sponsors," as the report refers to them) currently approved by the FDA to market mifepristone for abortion are Danco Laboratories, LLC, GenBioPro, Inc. (GBP), and Evita Solutions, LLC. Mifepristone is subject to a drug safety program called Risk Evaluation and Mitigation Strategies (REMS) meant to safeguard against potential serious side effects. The REMS include requirements for the sponsors of a drug as well as the prescribers. Under the program, prescribers must undergo a training and enrollment process to become certified to prescribe mifepristone.